Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after Fecal Microbiota Transplant in Inflammatory Bowel Disease.

Crohn’s disease fecal microbiota transplant inflammatory bowel disease microbial therapeutics microbiome ulcerative colitis

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
01 Feb 2023
Historique:
pubmed: 14 2 2023
medline: 14 2 2023
entrez: 13 2 2023
Statut: epublish

Résumé

Fecal Microbiota Transplant (FMT) has proven effective in treating recurrent Subjects with CD or UC were randomized to receive antibiotics and weekly FMT or placebo in addition to baseline medications. The treatment arm received seven days of antibiotics followed by FMT enema and then capsules weekly for seven weeks. We enrolled four subjects with CD and 11 with UC, ages 14-29 years. Due to weekly stool sampling, we were able to create a time series of alpha diversity, beta diversity and engraftment as they related to clinical response. Subjects exhibited a wide range of microbial diversity and donor engraftment as FMT progressed. Specifically, engraftment ranged from 26% to 90% at week 2 and 3% to 92% at two months. Consistent with the current literature, increases over time of both alpha diversity (p< 0.05) and donor engraftment (p< 0.05) correlated with improved clinical response. Additionally, our weekly time series enabled an investigation into the clinical and microbial correlates of engraftment at various time points. We discovered that the post-antibiotic but pre-FMT time point, often overlooked in FMT trials, was rich in microbial correlates of eventual engraftment. Greater residual alpha diversity after antibiotic treatment was positively correlated with engraftment and subsequent clinical response. Interestingly, a transient rise in the relative abundance of Lactobacillus was also positively correlated with engraftment, a finding that we recapitulated with our analysis of another FMT trial with publicly available weekly sequencing data. We found that higher residual alpha diversity and Lactobacillus blooms after antibiotic treatment correlated with improved engraftment and clinical response to FMT. Future studies should closely examine the host microbial communities pre-FMT and the impact of antibiotic preconditioning on engraftment and response.

Sections du résumé

Background UNASSIGNED
Fecal Microbiota Transplant (FMT) has proven effective in treating recurrent
Results UNASSIGNED
Subjects with CD or UC were randomized to receive antibiotics and weekly FMT or placebo in addition to baseline medications. The treatment arm received seven days of antibiotics followed by FMT enema and then capsules weekly for seven weeks. We enrolled four subjects with CD and 11 with UC, ages 14-29 years. Due to weekly stool sampling, we were able to create a time series of alpha diversity, beta diversity and engraftment as they related to clinical response. Subjects exhibited a wide range of microbial diversity and donor engraftment as FMT progressed. Specifically, engraftment ranged from 26% to 90% at week 2 and 3% to 92% at two months. Consistent with the current literature, increases over time of both alpha diversity (p< 0.05) and donor engraftment (p< 0.05) correlated with improved clinical response. Additionally, our weekly time series enabled an investigation into the clinical and microbial correlates of engraftment at various time points. We discovered that the post-antibiotic but pre-FMT time point, often overlooked in FMT trials, was rich in microbial correlates of eventual engraftment. Greater residual alpha diversity after antibiotic treatment was positively correlated with engraftment and subsequent clinical response. Interestingly, a transient rise in the relative abundance of Lactobacillus was also positively correlated with engraftment, a finding that we recapitulated with our analysis of another FMT trial with publicly available weekly sequencing data.
Conclusions UNASSIGNED
We found that higher residual alpha diversity and Lactobacillus blooms after antibiotic treatment correlated with improved engraftment and clinical response to FMT. Future studies should closely examine the host microbial communities pre-FMT and the impact of antibiotic preconditioning on engraftment and response.

Identifiants

pubmed: 36778473
doi: 10.1101/2023.01.30.23285033
pmc: PMC9915819
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NICHD NIH HHS
ID : K12 HD052896
Pays : United States

Auteurs

Yanjia Jason Zhang (YJ)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
Department of Biological Engineering, Massachusetts Institute of Technology 21 Ames St. Cambridge, MA, USA.
Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA.

Athos Bousvaros (A)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA.

Michael Docktor (M)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

Abby Kaplan (A)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

Paul A Rufo (PA)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

McKenzie Leier (M)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

Madison Weatherly (M)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

Lori Zimmerman (L)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

Le Thanh Tu Nguyen (LTT)

Department of Biological Engineering, Massachusetts Institute of Technology 21 Ames St. Cambridge, MA, USA.
Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA.

Brenda Barton (B)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

George Russell (G)

Gastroenterology/Nutrition, Maine Medical Center 22 Bramhall St. Portland, ME, USA.

Eric J Alm (EJ)

Department of Biological Engineering, Massachusetts Institute of Technology 21 Ames St. Cambridge, MA, USA.
Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA.

Stacy A Kahn (SA)

Gastroenterology/Nutrition, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.
IBD Center, Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA.

Classifications MeSH